← All trials
NCT04876534
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 18, 2019
- Primary completion
- Dec 18, 2022
- Completion date
- Dec 18, 2023
- First posted
- May 6, 2021
- Last posted
- May 11, 2021
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- A.O. Ospedale Maggiore di LodiLead sponsor
- University of PisaCollaborator
- Istituto Auxologico ItalianoCollaborator
- Azienda Ospedaliera Sant'Andrea, RomaCollaborator
- Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, MilanoOverall official - principal investigator
- Mauriziano Umberto I HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.